Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

IL-13

  • Home
  • IL-13
IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management
Posted inAllergy & Immunology Gastroenterology news

IL-13 Inhibition with Cendakimab: A New Frontier in Eosinophilic Esophagitis Management

Posted by MedXY By MedXY 12/31/2025
A Phase 3 trial demonstrates that cendakimab significantly reduces dysphagia days and improves histologic and endoscopic markers in patients with eosinophilic esophagitis, offering a targeted therapeutic approach for this chronic type 2 inflammatory condition.
Read More
Cendakimab: A Promising Therapeutic for Eosinophilic Esophagitis in Adolescents and Adults
Posted inGastroenterology news

Cendakimab: A Promising Therapeutic for Eosinophilic Esophagitis in Adolescents and Adults

Posted by MedXY By MedXY 09/26/2025
Cendakimab, a monoclonal antibody targeting IL-13, shows significant improvements in symptoms, histologic response, and endoscopic features in eosinophilic esophagitis, with a tolerable safety profile through 48 weeks.
Read More
  • Poverty Exposure in Standard-Risk Pediatric B-ALL Is Linked to Steroid-Resistance Programs and an Immunologically Suppressed Leukemia Microenvironment
  • Early ctDNA MRD After Two Cycles Identifies Distinct Relapse Risk Groups in Advanced Hodgkin Lymphoma
  • Transformative Survival Gains in Cystic Fibrosis: A Population-Level Evaluation of CFTR Modulator Therapy Effectiveness
  • More Enteral Protein Did Not Overcome Anabolic Resistance in Mechanically Ventilated Critical Illness
  • Persistent Challenges in Managing Monocular Deprivation Amblyopia: A Three-Decade Trend Analysis of Infant Unilateral Cataract Outcomes
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in